Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDIV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 123Melanoma 92Neoplasms 82Colorectal Neoplasms 62Squamous Cell Carcinoma of Head and Neck 61Neoplasm Metastasis 58Triple Negative Breast Neoplasms 49Carcinoma, Renal Cell 47Breast Neoplasms 38Lung Neoplasms 36Ovarian Neoplasms 32Pancreatic Neoplasms 30Head and Neck Neoplasms 29Stomach Neoplasms 28Urinary Bladder Neoplasms 26Carcinoma, Transitional Cell 26Parkinson Disease 4, Autosomal Dominant Lewy Body 23Endometrial Neoplasms 23Uterine Cervical Neoplasms 21Carcinoma, Hepatocellular 18Recurrence 15Esophageal Neoplasms 15Prostatic Neoplasms 14Lymphoma 14Carcinoma, Squamous Cell 12Small Cell Lung Carcinoma 11Kidney Neoplasms 11Cholangiocarcinoma 11Advanced Solid Tumor 11Solid Tumor 10

Interventions

pembrolizumab 1SH-1028 1Injections 12-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5-(2-hydroxy-3-morpholinopropyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo(3,2-c)azepin-4-ketone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Cancer × pembrolizumab × Clear all
NCT07123415 2025-11-19

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Aptabio Therapeutics, Inc.

Phase 1 Recruiting
110 enrolled
Other solid neoplasm

Advanced Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡